Literature DB >> 30404762

More unaffected first-degree relatives of essential tremor cases have mild cognitive deficits than age-matched controls.

James H Meyers1, Ruby Hickman1, Ashley D Cristal1, Pam Factor-Litvak2, Stephanie Cosentino3, Elan D Louis4.   

Abstract

BACKGROUND: In numerous case-control studies, essential tremor (ET) has been associated with cognitive impairment. ET is often familial. However, cognitive impairment has not been studied in family members of ET cases. Endophenotypes are measurable clinical characteristics that may be present in individuals with increased risk for disease; as such, they may be present before disease onset. We administered a global cognitive screen to first-degree relatives of ET cases (FD-ET) and age-matched controls (Co).
METHODS: We administered the Montreal Cognitive Assessment (MoCA) to 156 FD-ET and 73 Co, none of whom were diagnosed with ET or reported tremor. MoCA <26 was considered suggestive of cognitive impairment.
RESULTS: FD-ET and Co were similar with respect to age (60.1 ± 8.3 vs. 60.9 ± 7.4 years) and numerous demographic factors. FD-ET and Co also had similar MoCA scores; however, 34 of 156 (21.8%) FD-ET had a MoCA score <26 vs only 5 (6.9%) of 73 Co (p = 0.004). In a univariate logistic regression model, FD-ET were 3.79 times more likely to have a low (<26) MoCA than were Co (odds ratio = 3.79, p = 0.008). In a multivariate logistic regression model, adjusting for age and other covariates, FD-ET were 4.83 times more likely to have a low MoCA than were Co (odds ratio = 4.83, p = 0.003).
CONCLUSION: More FD-ET had low MoCA scores when compared with Co. These data provide additional support for the scientific notions that (1) cognitive difficulties are a disease-associated feature of ET and (2) there may be a pre-tremor phase of illness in ET.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Endophenotype; Epidemiology; Essential tremor; Genetics; Mild cognitive impairment; Pre-motor

Mesh:

Year:  2018        PMID: 30404762      PMCID: PMC6488412          DOI: 10.1016/j.parkreldis.2018.10.030

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  32 in total

1.  Comparison of clinical vs. electrophysiological methods of diagnosing of essential tremor.

Authors:  E D Louis; S L Pullman
Journal:  Mov Disord       Date:  2001-07       Impact factor: 10.338

2.  The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research.

Authors:  E D Louis; R Ottman; B Ford; S Pullman; M Martinez; S Fahn; W A Hauser
Journal:  Neuroepidemiology       Date:  1997       Impact factor: 3.282

3.  Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

Authors:  A T Beck; R A Steer; R Ball; W Ranieri
Journal:  J Pers Assess       Date:  1996-12

4.  Unaffected first-degree relatives of essential tremor cases have more imbalance than age-matched control subjects.

Authors:  Elan D Louis; James H Meyers; Ashley D Cristal; Ruby Hickman; Pam Factor-Litvak
Journal:  Parkinsonism Relat Disord       Date:  2018-03-13       Impact factor: 4.891

5.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

6.  Mild cognitive impairment in moderate to severe COPD: a preliminary study.

Authors:  Sylvia Villeneuve; Véronique Pepin; Shady Rahayel; Josie-Anne Bertrand; Myriam de Lorimier; Amanda Rizk; Catherine Desjardins; Simon Parenteau; François Beaucage; Steve Joncas; Oury Monchi; Jean-François Gagnon
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

7.  Comparative Burden of Subclinical Tremor in a Cohort of Normal Individuals Stratified by Familial Risk for Essential Tremor.

Authors:  Elan D Louis; James H Meyers; Olufunmilayo M Badejo; Ashley D Cristal; Ruby Hickman; Pam Factor-Litvak
Journal:  Neuroepidemiology       Date:  2018-01-16       Impact factor: 3.282

8.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Authors:  Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

Review 9.  Is there a Premotor Phase of Essential Tremor?

Authors:  Abhishek Lenka; Julian Benito-León; Elan D Louis
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-10-05

10.  Cognitive Dysfunction Is Associated with Greater Imbalance and Falls in Essential Tremor.

Authors:  Elan D Louis; Sarah Kellner; Sarah Morgan; Kathleen Collins; Brittany Rohl; Edward D Huey; Stephanie Cosentino
Journal:  Front Neurol       Date:  2017-04-19       Impact factor: 4.003

View more
  3 in total

1.  The Conundrum of Dystonia in Essential Tremor Patients: How does One Classify these Cases?

Authors:  Wenqin Du; Peter G Bain; Giovanni Defazio; Joseph Jankovic; Christine Y Kim; E K Tan; Marie Vidailhet; Elan D Louis
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2022-05-13

2.  The spiral axis: A comparison of unaffected first-degree relatives of essential tremor cases vs. controls.

Authors:  Elan D Louis; Hollie N Dowd; Mazen Elkurd
Journal:  J Neurol Sci       Date:  2021-01-28       Impact factor: 3.181

3.  Association of Essential Tremor With Dementia and Affective Disorders: A Meta-Analysis.

Authors:  Yajun Shang; Xinjie Chen; Mingda Ai; Xiaoran Gao; Shujuan Dai; Mingjie Zhao; Cen Yang; Liangfeng Wang; Junyan Zhang; Lianmei Zhong; Tianhao Bao; Xiaolei Liu
Journal:  Front Neurol       Date:  2022-03-17       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.